Part of the rationale for developing these compounds relates to the possibility of correcting the aberrant stimulus–activity coupling observed at the CCK1R in a membrane environment with high cholesterol, as sometimes seen in obesity. The gene discussed is CCKAR; the disease is obesity due to melanocortin 4 receptor deficiency.